Loading...

We've got a brand new version of Simply Wall St! Try it out

Callitas Health

CNSX:LILY
Snowflake Description

Slightly overvalued with imperfect balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
LILY
CNSX
€3M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Callitas Health Inc., a biomedical technology company, develops and commercializes technologies for obesity, weight management, and female health and wellness in Canada. The last earnings update was 297 days ago. More info.


Add to Portfolio Compare Print
LILY Share Price and Events
7 Day Returns
0%
CNSX:LILY
-5.9%
CA Pharmaceuticals
1.3%
CA Market
1 Year Returns
-
CNSX:LILY
-46.7%
CA Pharmaceuticals
-0.1%
CA Market
LILY Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Callitas Health (LILY) 0% 0% 10% - -89.5% -
CA Pharmaceuticals -5.9% -3.4% -24.8% -46.7% 217.3% 286.4%
CA Market 1.3% 4.2% 1.6% -0.1% 8.4% 5.7%
1 Year Return vs Industry and Market
  • No trading data on LILY.
  • No trading data on LILY.
Price Volatility
LILY
Industry
5yr Volatility vs Market

LILY Value

 Is Callitas Health undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Callitas Health to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Callitas Health.

CNSX:LILY Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 6.9%
Perpetual Growth Rate 10-Year CA Government Bond Rate 1.9%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for CNSX:LILY
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year CA Govt Bond Rate 1.9%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.7
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.698 (1 + (1- 26.5%) (8.49%))
0.827
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.83
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.95% + (0.827 * 5.96%)
6.88%

Discounted Cash Flow Calculation for CNSX:LILY using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Callitas Health is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

CNSX:LILY DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (CAD, Millions) Source Present Value
Discounted (@ 6.88%)
2020 3.96 Est @ 40.15% 3.71
2021 5.10 Est @ 28.69% 4.46
2022 6.15 Est @ 20.66% 5.04
2023 7.08 Est @ 15.05% 5.42
2024 7.86 Est @ 11.12% 5.64
2025 8.52 Est @ 8.37% 5.72
2026 9.07 Est @ 6.44% 5.69
2027 9.53 Est @ 5.09% 5.60
2028 9.93 Est @ 4.15% 5.46
2029 10.27 Est @ 3.49% 5.28
Present value of next 10 years cash flows CA$52.00
CNSX:LILY DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= CA$10.27 × (1 + 1.95%) ÷ (6.88% – 1.95%)
CA$212.47
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= CA$212.47 ÷ (1 + 6.88%)10
CA$109.26
CNSX:LILY Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= CA$52.00 + CA$109.26
CA$161.26
Equity Value per Share
(CAD)
= Total value / Shares Outstanding
= CA$161.26 / 45.21
CA$3.57
CNSX:LILY Discount to Share Price
Calculation Result
Exchange Rate CAD/EUR
(Reporting currency to currency of DB:T3F3)
0.685
Value per Share
(EUR)
= Value per Share in CAD x Exchange Rate (CAD/EUR)
= CA$3.57 x 0.685
€2.44
Non-primary Listing Adjustment Factor 1 share in CNSX:LILY represents 1.83335x of DB:T3F3
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
1.83335x
Value per Share
(Listing Adjusted, CAD)
= Value per Share (EUR) x Listing Adjustment Factor
= € 2.44 x 1.83335
CA$4.48
Value per share (CAD) From above. CA$4.48
Current discount Discount to share price of CA$0.11
= -1 x (CA$0.11 - CA$4.48) / CA$4.48
97.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Callitas Health is available for.
Intrinsic value
>50%
Share price is CA$0.11 vs Future cash flow value of CA$4.48
Current Discount Checks
For Callitas Health to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Callitas Health's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Callitas Health's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Callitas Health's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Callitas Health's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:LILY PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in CAD CA$-0.22
DB:T3F3 Share Price ** DB (2019-07-11) in EUR €0.06
DB:T3F3 Share Price converted to CAD reporting currency Exchange rate (EUR/ CAD) 1.459 CA$0.09
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 15.3x
Canada Market PE Ratio Median Figure of 539 Publicly-Listed Companies 14.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Callitas Health.

CNSX:LILY PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= DB:T3F3 Share Price ÷ EPS (both in CAD)

= 0.09 ÷ -0.22

-0.4x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Callitas Health is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Callitas Health is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Callitas Health's expected growth come at a high price?
Raw Data
CNSX:LILY PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.4x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.56x
Canada Market PEG Ratio Median Figure of 245 Publicly-Listed Companies 1.02x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Callitas Health, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Callitas Health's assets?
Raw Data
CNSX:LILY PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in CAD CA$-0.04
DB:T3F3 Share Price * DB (2019-07-11) in EUR €0.06
DB:T3F3 Share Price converted to CAD reporting currency Exchange rate (EUR/ CAD) 1.459 CA$0.09
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.36x
Canada Market PB Ratio Median Figure of 2,457 Publicly-Listed Companies 1.43x
CNSX:LILY PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= DB:T3F3 Share Price ÷ Book Value per Share (both in CAD)

= 0.09 ÷ -0.04

-2.36x

* Primary Listing of Callitas Health.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Callitas Health has negative assets, we can't compare the value of its assets to the CA Pharmaceuticals industry average.
X
Value checks
We assess Callitas Health's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Callitas Health has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

LILY Future Performance

 How is Callitas Health expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Callitas Health has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
97.7%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Callitas Health expected to grow at an attractive rate?
  • Unable to compare Callitas Health's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Callitas Health's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Callitas Health's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:LILY Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 97.7%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 56.5%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:LILY Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (11 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:LILY Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2018-09-30 1 3 -7
2018-06-30 1 1 -8
2018-03-31 1 -2 -8
2017-12-31 1 -3 -9
2017-09-30 0 -6 -3
2017-06-30 0 -6 -3
2017-03-31 0 -3 -3
2016-12-31 -2 -2
2016-09-30 -1 -4
2016-06-30 0 -3
2016-03-31 0 -3
2015-12-31 -1 -4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Callitas Health is high growth as no earnings estimate data is available.
  • Unable to determine if Callitas Health is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:LILY Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (11 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Callitas Health Company Filings, last reported 11 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:LILY Past Financials Data
Date (Data in CAD Millions) EPS *
2018-09-30 -0.22
2018-06-30 -0.26
2018-03-31 -0.30
2017-12-31 -0.38
2017-09-30 -0.17
2017-06-30 -0.21
2017-03-31 -0.33
2016-12-31 -0.33
2016-09-30 -1.38
2016-06-30 -1.32
2016-03-31 -1.22
2015-12-31 -1.78

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Callitas Health will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Callitas Health's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  2. Callitas Health's competitive advantages and company strategy can generally be found in its financial reports archived here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Callitas Health's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Callitas Health has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

LILY Past Performance

  How has Callitas Health performed over the past 5 years?

  • Callitas Health's last earnings update was 297 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Callitas Health's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Callitas Health does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Callitas Health's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Callitas Health's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Callitas Health's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Callitas Health Company Filings, last reported 11 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:LILY Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 0.78 -7.00 2.23 0.13
2018-06-30 0.77 -7.96 2.83 0.27
2018-03-31 0.79 -7.88 2.83 0.32
2017-12-31 0.64 -8.58 3.37 0.46
2017-09-30 0.47 -2.97 3.37 0.44
2017-06-30 0.27 -2.71 3.38 0.31
2017-03-31 0.03 -3.09 2.97 0.25
2016-12-31 -2.07 2.30 0.11
2016-09-30 -3.96 3.42
2016-06-30 -3.49 3.05
2016-03-31 -3.38 3.51
2015-12-31 -3.98 3.86
2015-09-30 -1.66 1.96
2015-06-30 -1.30 1.56
2015-03-31 -0.64 1.12
2014-12-31 -0.35 0.81
2014-09-30 -17.40 1.05
2014-06-30 -17.49 1.21
2014-03-31 -17.12 0.98
2013-12-31 -16.99 0.88
2013-09-30 -0.53 0.85
2013-06-30 -0.35 0.64
2013-03-31 -0.72 0.71
2012-12-31 -0.81 0.80
2012-09-30 -6.36 0.87

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Callitas Health has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Callitas Health has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Callitas Health improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Callitas Health's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Callitas Health has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

LILY Health

 How is Callitas Health's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Callitas Health's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Callitas Health's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Callitas Health has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Callitas Health's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Callitas Health has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Callitas Health Company Filings, last reported 11 months ago.

CNSX:LILY Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 -1.22 0.34 0.00
2018-06-30 -0.85 0.34 0.00
2018-03-31 -0.36 0.26 0.00
2017-12-31 -0.13 0.26 0.02
2017-09-30 4.41 0.30 0.18
2017-06-30 2.45 0.45 0.11
2017-03-31 2.83 0.45 0.35
2016-12-31 0.22 0.52 0.72
2016-09-30 0.75 0.76 1.39
2016-06-30 -0.24 0.14 0.19
2016-03-31 -0.64 0.24 0.00
2015-12-31 -1.10 0.22 0.00
2015-09-30 1.17 0.37 0.00
2015-06-30 1.65 0.36 0.25
2015-03-31 0.60 0.07 0.48
2014-12-31 -0.20 0.07 0.28
2014-09-30 -0.31 0.10 0.22
2014-06-30 -0.20 0.39 0.59
2014-03-31 -0.98 0.36 0.04
2013-12-31 -1.13 0.39 0.05
2013-09-30 15.61 0.23 0.02
2013-06-30 15.40 0.27 0.00
2013-03-31 14.73 0.23 0.02
2012-12-31 14.82 0.20 0.04
2012-09-30 15.11 0.18 0.08
  • Callitas Health has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Callitas Health's debt level has increased considering it has negative shareholder equity.
  • Debt is well covered by operating cash flow (840.7%, greater than 20% of total debt).
  • Unable to confirm if the interest payments on Callitas Health's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess Callitas Health's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Callitas Health has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

LILY Dividends

 What is Callitas Health's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Callitas Health dividends.
If you bought CA$2,000 of Callitas Health shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Callitas Health's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Callitas Health's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:LILY Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Callitas Health has not reported any payouts.
  • Unable to verify if Callitas Health's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Callitas Health's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Callitas Health has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Callitas Health's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Callitas Health afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Callitas Health has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

LILY Management

 What is the CEO of Callitas Health's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
James Thompson
TENURE AS CEO 1.7 years
CEO Bio

Mr. James M. Thompson is the President and Chief Executive Officer of Callitas Health Inc. since June 4, 2018. Mr. Thompson served as Chief Operating Officer of Callitas Health Inc. until January 2018 and served as its Interim President & Chief Executive Officer since January 2018 until June 4, 2018. He has multiple granted and pending patent applications and has managed the development, testing, production and distribution of all types of healthcare products worldwide over the last 18 plus years. Mr. Thompson was the Managing Member at 40 J's LLC, the private healthcare development corporation whose primary assets were acquired in early 2017 by Callitas Therapeutics. Mr. Thompson has a Bachelor's of Science in Biomedical Engineering and a double major in Finance from Washington University in St. Louis, MO and an Executive MBA from Xavier University in Cincinnati, OH.

CEO Compensation
  • Insufficient data for James to compare compensation growth.
  • Insufficient data for James to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team Tenure

Average tenure and age of the Callitas Health management team in years:

1.9
Average Tenure
50
Average Age
  • The average tenure for the Callitas Health management team is less than 2 years, this suggests a new team.
Management Team

George Tsafalas

TITLE
Senior Business Consultant
COMPENSATION
CA$45K
AGE
50
TENURE
2.5 yrs

James Thompson

TITLE
President & CEO
TENURE
1.7 yrs

Gary Stephens

TITLE
Chief Financial Officer
TENURE
2.3 yrs

Joshua Maurice

TITLE
Vice President of Sales & Business Development
TENURE
1.9 yrs

Laura A. Berman

TITLE
Chief Health Advisor
AGE
50
TENURE
1.7 yrs

Gregory Smith

TITLE
Chief Medical Cannabis Advisor
TENURE
1.3 yrs

Bill Rodgers

TITLE
President
AGE
61

Brian Keane

TITLE
Senior Business Consultant & Director
TENURE
2.6 yrs
Board of Directors Tenure

Average tenure of the Callitas Health board of directors in years:

3.4
Average Tenure
  • The tenure for the Callitas Health board of directors is about average.
Board of Directors

Bill Rodgers

TITLE
President
AGE
61
TENURE
2.6 yrs

Brian Keane

TITLE
Senior Business Consultant & Director
TENURE
3.4 yrs

Rick Skeith

TITLE
Director
AGE
66
TENURE
4.8 yrs

Christopher Andrews

TITLE
Director
TENURE
4.3 yrs

Kim Whittemore

TITLE
Director
TENURE
2.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
X
Management checks
We assess Callitas Health's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Callitas Health has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

LILY News

Simply Wall St News

LILY Company Info

Description

Callitas Health Inc., a biomedical technology company, develops and commercializes technologies for obesity, weight management, and female health and wellness in Canada. The company offers obesity drug C-103, a reformulation of Orlistat; ToConceive, a fertility enhancing moisturizer; and Extrinsa for female sexual dysfunction solutions. The company was formerly known as M Pharmaceutical Inc. and changed its name to Callitas Health Inc. in September 2017. Callitas Health Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Details
Name: Callitas Health Inc.
LILY
Exchange: CNSX
Founded: 2003
€3,957,982
45,209,162
Website: http://callitas.com
Address: Callitas Health Inc.
1055 Dunsmuir Street,
Suite 734,
Vancouver,
British Columbia, V7X 1B1,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
DB T3F3 Common Shares Deutsche Boerse AG DE EUR 18. Oct 2005
OTCPK MPHM.F Common Shares Pink Sheets LLC US USD 18. Oct 2005
CNSX LILY Common Shares Canadian National Stock Exchange CA CAD 18. Oct 2005
DB A2GSU1 COM NPV Deutsche Boerse AG DE EUR 22. Sep 2019
Number of employees
Current staff
Staff numbers
0
Callitas Health employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/22 00:52
End of day share price update: 2019/07/11 00:00
Last earnings filing: 2018/11/29
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.